Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-330 vs Amlodipine in Hypertension
NCT02586311Phase 3Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2016
- Primary completion
- Aug 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of candesartan, amlodipine in hypertension (HTN), sponsored by Chong Kun Dang Holdings. Started Jan 2016; status: completed.
02
Drugs
candesartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02586311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586311.